Shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $4.80.
AMRX has been the subject of a number of recent research reports. Piper Sandler increased their target price on Amneal Pharmaceuticals from $3.00 to $5.00 and gave the stock an “overweight” rating in a report on Monday, August 7th. Truist Financial upped their price target on Amneal Pharmaceuticals from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Wednesday. Barclays lifted their price objective on Amneal Pharmaceuticals from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Friday, August 4th. StockNews.com started coverage on Amneal Pharmaceuticals in a report on Tuesday. They issued a “buy” rating on the stock. Finally, TheStreet upgraded Amneal Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Tuesday, August 15th.
Amneal Pharmaceuticals Price Performance
Insider Transactions at Amneal Pharmaceuticals
In other Amneal Pharmaceuticals news, EVP Andrew S. Boyer sold 29,302 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $4.13, for a total transaction of $121,017.26. Following the transaction, the executive vice president now directly owns 244,739 shares in the company, valued at approximately $1,010,772.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 26.78% of the company’s stock.
Institutional Trading of Amneal Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas grew its holdings in shares of Amneal Pharmaceuticals by 19.0% during the second quarter. Teacher Retirement System of Texas now owns 720,101 shares of the company’s stock valued at $2,232,000 after buying an additional 114,899 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC bought a new stake in Amneal Pharmaceuticals in the 1st quarter worth about $32,000. CM Management LLC increased its stake in Amneal Pharmaceuticals by 83.3% in the 2nd quarter. CM Management LLC now owns 275,000 shares of the company’s stock valued at $853,000 after buying an additional 125,000 shares during the last quarter. Brandywine Global Investment Management LLC bought a new position in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $1,245,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Amneal Pharmaceuticals by 35.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 628,338 shares of the company’s stock worth $1,948,000 after buying an additional 165,137 shares during the last quarter. 31.82% of the stock is owned by institutional investors.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
- Five stocks we like better than Amneal Pharmaceuticals
- Growth Stocks: What They Are, Examples and How to Invest
- Investing in large cap stocks: Diving into big caps
- The How and Why of Investing in Gold Stocks
- Why you can make Vertex Pharmaceuticals a buy on any pullback
- 3 Tickers Leading a Meme Stock Revival
- Occidental Petroleum: Another bounce from the buy zone
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.